IP Library Granted Patent US 8,901,188
Granted Patent B2
US 8,901,188 · App. 13/493,209 · Granted Dec 2, 2014

Antimicrobial polyurethane foam and process to make the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,901,188
App. No.
13/493,209
Granted
Dec 2, 2014
Kind
B2
Abstract

An antimicrobial polyurethane foam that is formed from: a multi-functional isocyanate component; an aqueous polyol component reactive with the multi-functional isocyanate component; an antimicrobial metallic compound; and a complexing agent. The complexing agent is used to form a stable blend of the antimicrobial metallic compound with the polyol component. Exemplary complexing agents include amine compounds, ammonium-containing compounds and ammonia as well as combinations these compounds. The antimicrobial metallic compound can be a silver, zinc or copper compound. Desirably, the antimicrobial metallic compound is silver saccharinate. A process of making the antimicrobial polyurethane foam and stable blends used in the manufacture of the antimicrobial polyurethane foam are also disclosed.

Claims (33)

1. A process for producing an antimicrobial polyurethane foam comprising:

providing an aqueous polyol component;

adding an antimicrobial metallic compound and a complexing agent to form a complex that is soluble in the aqueous polyol component;

solubilizing the antimicrobial metallic compound complex in the aqueous polyol component to form a stable blend;

mixing a multi-functional isocyanate component with the stable blend;

reacting the multi-functional isocyanate component with the aqueous polyol to form a polyurethane foam incorporating the antimicrobial metallic compound; and

allowing the complexing agent to dissipate such that the antimicrobial metallic compound is present as substantially only the antimicrobial metallic compound in the finished foam.

2. The process of claim 1 , wherein the antimicrobial metallic compound is a silver, zinc or copper compound.

3. The process of claim 1 , wherein the complexing agent is selected from amine compounds, ammonium-containing compounds and ammonia.

4. The process of claim 3 , wherein the complexing agent is a catalyst for the reaction of the multi-functional isocyanate component with the aqueous polyol.

5. The process of claim 2 , wherein the antimicrobial metallic compound is selected from silver saccharinate.

6. The process of claim 1 , further comprising the step of adding a chain extender.

7. The process of claim 1 , wherein the process effects a substantially uniform distribution of the antimicrobial metallic compound within the foam matrix during the process of making the antimicrobial polyurethane foam.

8. A method for producing a stable blend used in the manufacture of antimicrobial polyurethane materials, the method comprising:

providing an aqueous polyol component;

adding an antimicrobial metallic compound and a complexing agent to form a complex that is soluble in the aqueous polyol component; and

solubilizing the antimicrobial metallic compound complex in the aqueous polyol component to form a stable blend,

wherein the antimicrobial metallic compound complex of the stable blend is adapted, upon mixing with a multi-functional isocyanate component and reacting to form a polyurethane foam incorporating the antimicrobial metallic compound, to allow dissipation of the complexing agent such that the antimicrobial metallic compound is present as substantially only the antimicrobial metallic compound in the finished polyurethane foam.

9. The method of claim 8 , wherein the antimicrobial metallic compound is a silver, zinc or copper compound.

10. The method of claim 8 , wherein the complexing agent is selected from amine compounds, ammonium-containing compounds and ammonia.

11. The method of claim 8 , wherein the complexing agent is a catalyst for the reaction of the multi-functional isocyanate component with the aqueous polyol.

12. An antimicrobial polyurethane foam produced according to the process of claim 1 , the antimicrobial polyurethane foam comprising:

a flexible matrix of polyurethane material defining a plurality of open cells; and

an antimicrobial metallic material uniformly distributed throughout the matrix.

13. The antimicrobial foam of claim 12 , further comprising silver nanoparticles that impart a permanent color to the foam in the visible portion of the UV-VIS spectrum without the use of a colorant wherein the color is not inherent to the reactive components used to produce the foam or is attributed to other additives or ingredients present in the foam.

14. The antimicrobial foam of claim 12 , wherein the foam is hydrophilic, absorbent, and is resistant to discoloration by ambient light and is resistant to the discoloration induced by ethylene oxide (ETO) and electron beam (E-beam) irradiation sterilization processes.

15. The antimicrobial foam of claim 12 , wherein the foam sustains antimicrobial activity against gram positive bacteria, gram negative bacteria and fungi for more than 7 days by releasing therapeutically effective amount of metal ions.

16. The antimicrobial foam of claim 13 , wherein the foam is hydrophilic, absorbent, and is resistant to discoloration by ambient light and is resistant to the discoloration induced by ethylene oxide (ETO) and electron beam (E-beam) irradiation sterilization processes.

17. The antimicrobial foam of claim 13 , wherein the foam sustains antimicrobial activity against gram positive bacteria, gram negative bacteria and fungi for more than 7 days by releasing therapeutically effective amount of metal ions.

18. An antimicrobial polyurethane foam produced according to the process of claim 1 , the antimicrobial polyurethane foam comprising:

a flexible matrix of polyurethane material defining a plurality of open cells; and

antimicrobial silver nanoparticles uniformly distributed throughout the matrix,

wherein the silver nanoparticles impart a permanent color to the foam in the visible portion of the UV-VIS spectrum without the use of a colorant wherein the color is not inherent to the reactive components used to produce the foam or is attributed to other additives or ingredients present in the foam.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jun 30, 2022
From: CITIBANK, N.A.
To: AVENT, INC.; AVANOS MEDICAL SALES, LLC
Reel/Frame 060557/0062 →
SECURITY INTEREST Recorded Jun 24, 2022
From: AVENT, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060441/0445 →
INTELLECTUAL PROPERTY SECURITY INTEREST ASSIGNMENT AGREEMENT Recorded Jan 23, 2019
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: CITIBANK, N.A.
Reel/Frame 048173/0137 →
SECURITY INTEREST Recorded Apr 6, 2015
From: AVENT, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 035375/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2015
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: AVENT, INC.
Reel/Frame 034753/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2014
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: AVENT, INC.
Reel/Frame 034182/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2012
From: KARANDIKAR, BHALCHANDRA M.; GIBBINS, BRUCE LANCE
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 028586/0527 →